{"groups":[{"description":"Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"FG000","title":"Soft Tissue Sarcoma"},{"description":"Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \\[de-differentiated or mesenchymal\\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"FG001","title":"Bone Sarcoma"},{"description":"Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks","id":"FG002","title":"Expansion Cohort"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"60"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"60"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}